Latanoprost

Phase III trial to enroll 420 men across up to 10 clinical sites in Canada First patient has now been dosed in the Company’s Phase III trial evaluating TH07 TH07 is a patented prescription triple-combination topical therapy targeting multiple pathways involved in hair loss Androgenic alopecia affects hundreds of millions of men worldwide MONTRÉAL--(BUSINESS WIRE)--Triple Hair Group Inc. (“ Triple Hair ” or the “ Company ”), a company specializing in the development of innovative treatments for androgenic alopecia (pattern baldness), today announced that the first patient has been dosed in its Phase III clinical trial in Canada evaluating TH07, the Company’s patented prescription topical treatment for male pattern hair loss. The Phase III clinical trial (NCT07435012) is designed to evaluate the safety and efficacy of TH07 in men with androgenic alopecia. TH07 is a patented prescription topical spray formulation that combines three active ingredients, minoxidil, finasteride, and latanoprost, each of which has demonstrated relevance to hair-growth biology through approved use and published scientific literature. This 24-week, randomized, double-blind, placebo-controlled, multicentre study is expected to enroll 420 male participants with moderate to moderately advanced androgenic alopecia across up to 10 clinical sites in Canada. Additional information regarding the trial and enrollment criteria is available at: . "The dosing of the first patient in our Phase III trial marks an important milestone for Triple Hair and the continued advancement of TH07," said Jean-Philippe Gravel, President and CEO of Triple Hair. " Androgenic alopecia affects hundreds of millions of men globally and remains an area of significant unmet need, with limited effective treatment options available. We believe TH07’s differentiated multi-mechanism approach has the potential to offer a meaningful new prescription treatment option in a large and underserved market, and we look forward to advancing the program and generating robust clinical data through this pivotal study.” “Male pattern baldness remains one of the most common dermatological conditions affecting men," added Dr. Martin Braun, Principal Medical Investigator of Triple Hair's Phase III trial. "This study is expected to provide important data on whether a multi-mechanism topical therapy such as TH07 can improve treatment outcomes for patients.” About TH07 TH07 is a patented prescription triple-combination topical therapy that combines minoxidil, finasteride and latanoprost, three pharmacologically active agents that target distinct biological pathways involved in androgenic alopecia. The therapy is designed to address multiple mechanisms associated with hair loss by: stimulating hair follicle activity, reducing androgen-mediated follicle miniaturization, and supporting prolonged hair growth cycles. By integrating these complementary mechanisms in a single topical formulation, TH07 is designed to simultaneously target several key drivers of hair loss. TH07 has previously demonstrated encouraging results in earlier clinical studies, where 82% of participants experienced positive outcomes ranging from moderate to dense hair regrowth, supporting its continued development in Phase III evaluation. About Triple Hair Triple Hair Group Inc. is a Canadian biotechnology company focused on the development of innovative therapies for androgenic alopecia, a condition affecting hundreds of millions of men and women worldwide. The global hair-loss treatment market was valued at approximately US$8.8 billion in 2023 and is projected to reach over US$16 billion by 2030, reflecting the significant demand for safe and effective treatment options. Triple Hair’s lead product candidate, TH07, is a patented prescription topical therapy currently in Phase III clinical development. For more information, visit the Company’s website, at . Forward-Looking Statements This press release may contain forward-looking statements, which are subject to certain factors, including risks and uncertainties, that could cause actual results to differ materially from those currently anticipated by the Company. These risks include, among others, the possibility that the Phase III clinical trial may not be successful or that TH07 may not obtain regulatory approval. Accordingly, future events and results may differ materially from those currently expected by management. Readers are cautioned not to place undue reliance on forward-looking statements. Contacts Triple Hair Group Jean-Philippe Gravel President and CEO investors@triplehair.ca

ROCHESTER, Minn., March 25, 2026 /PRNewswire/ -- Nanodropper today announced results from a randomized clinical trial demonstrating that microvolume eyedrop delivery using the Nanodropper adaptor achieved greater intraocular pressure reduction, fewer adverse effects, and significantly reduced premature bottle exhaustion compared with conventional eyedrops in patients with glaucoma or ocular hypertension. Continue Reading The study, "Real-world efficacy, safety, and usability of a microvolume eyedrop delivery device in glaucoma: a prospective randomized crossover trial," was published in the Journal of Cataract & Refractive Surgery and evaluated real-world use of microdrops delivered via the Nanodropper Adaptor compared to conventional drops. Study: Nanodropper reduces bottle waste by 80% and improves pressure control in glaucoma vs standard drops. Post this Key Study Findings In the prospective, examiner-masked, randomized crossover trial, adults with stable primary open-angle glaucoma or ocular hypertension using either latanoprost 0.005% or timolol maleate 0.5% monotherapy self-administered conventional drops or Nanodropper microdrops for 12 weeks before switching treatments. Results showed clear advantages for microvolume delivery: Superior intraocular pressure (IOP) reduction: Microdrops: 1.6 mm Hg reduction from baseline Conventional drops: 0.13 mm Hg reduction 80% reduction in premature bottle exhaustion: 83% of patients ran out of drops early with conventional bottles Only 17% experienced early exhaustion using Nanodropper Fewer reported side effects: 83% of patients reported adverse effects with conventional drops 62% reported adverse effects with microdrops Most study participants also reported that the Nanodropper device was easy to administer and helped prevent medication waste. Addressing a Major Challenge in Glaucoma Treatment Although the eye can retain only 7–10 microliters of fluid, conventional eyedrops typically deliver 25–60 microliters per drop, resulting in overflow, wasted medication, and increased systemic exposure. By reducing drop volume, the Nanodropper adaptor increases the number of usable doses per bottle and may help patients avoid interruptions in therapy caused by running out of medication early. Study authors concluded that microdrop delivery using the Nanodropper adaptor improved intraocular pressure reduction while decreasing premature bottle exhaustion and non-systemic adverse effects, suggesting the technology may enhance medication adherence and long-term glaucoma management. "These findings are very encouraging, adding to the growing body of evidence that supports the use of microdrops for instillation of a wide variety of eyedrop medications, including in the at-home setting," said Dr. Eric Grewal, Medical Director of Nanodropper and a key author on the study. "The additional reduction in IOP achieved with the Nanodropper for subjects already on standard treatment suggests that microdrops could maximize pressure control from existing regimens, potentially delivering extra therapeutic benefit even without medication changes or escalation of therapy." "We are pleased to see the Nanodropper validated as a low-cost solution for delivering IOP-lowering medications and defraying premature bottle exhaustion," adds Dr. Allisa Song, Chief Executive Officer of Nanodropper. "Every bit of pressure control matters for patients with glaucoma and ocular hypertension." The full journal article can be viewed using the following link: About Nanodropper Nanodropper develops precision microvolume delivery technology designed to reduce eyedrop size, minimize medication waste, and improve patient usability in ophthalmic treatments. Nanodroppers are available for patients, clinics and doctors to purchase at Nanodropper.com Media Contact: Ariana Rodriguez Marketing Manager [email protected] SOURCE Nanodropper 21% more press release views with Request a Demo